XML 59 R44.htm IDEA: XBRL DOCUMENT
v3.25.4

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information | The following tables set forth information about the Company’s reportable segments, along with the items necessary to reconcile the segment information to the totals reported in the Company’s consolidated statements of operations as follows (in thousands):
| For the Year Ended December 31, 2025 |
| Pharmacy Solutions |  |  | Provider Services |  |  | Total Segments |
Product revenue | $ | 11,445,777 |  |  | $ | — |  |  | $ | 11,445,777 |
Service revenue |  | — |  |  |  | 1,464,787 |  |  |  | 1,464,787 |
Cost of drugs |  | 9,782,109 |  |  |  | — |  |  |  | 9,782,109 |
Cost of services |  | — |  |  |  | 885,356 |  |  |  | 885,356 |
Other direct costs (1) |  | 725,322 |  |  |  | — |  |  |  | 725,322 |
Segment selling, general, and administrative expenses (2) |  | 502,042 |  |  |  | 374,256 |  |  |  | 876,298 |
Segment depreciation and amortization expense (3) |  | 107,198 |  |  |  | 27,479 |  |  |  | 134,677 |
Segment EBITDA | $ | 543,502 |  |  | $ | 232,654 |  |  | $ | 776,156 |
| For the Year Ended December 31, 2024 |
| Pharmacy Solutions |  |  | Provider Services |  |  | Total Segments |
Product revenue | $ | 8,754,282 |  |  | $ | — |  |  | $ | 8,754,282 |
Service revenue |  | — |  |  |  | 1,317,932 |  |  |  | 1,317,932 |
Cost of drugs |  | 7,368,426 |  |  |  | — |  |  |  | 7,368,426 |
Cost of services |  | — |  |  |  | 797,286 |  |  |  | 797,286 |
Other direct costs (1) |  | 640,075 |  |  |  | — |  |  |  | 640,075 |
Segment selling, general, and administrative expenses (2) |  | 462,219 |  |  |  | 340,034 |  |  |  | 802,253 |
Segment depreciation and amortization expense (3) |  | 111,103 |  |  |  | 24,675 |  |  |  | 135,778 |
Segment EBITDA | $ | 394,665 |  |  | $ | 205,287 |  |  | $ | 599,952 |
| For the Year Ended December 31, 2023 |
| Pharmacy Solutions |  |  | Provider Services |  |  | Total Segments |
Product revenue | $ | 6,522,450 |  |  | $ | — |  |  | $ | 6,522,450 |
Service revenue |  | — |  |  |  | 1,168,566 |  |  |  | 1,168,566 |
Cost of drugs |  | 5,291,630 |  |  |  | — |  |  |  | 5,291,630 |
Cost of services |  | — |  |  |  | 711,304 |  |  |  | 711,304 |
Other direct costs (1) |  | 549,086 |  |  |  | — |  |  |  | 549,086 |
Segment selling, general, and administrative expenses (2) |  | 426,521 |  |  |  | 310,747 |  |  |  | 737,268 |
Segment depreciation and amortization expense (3) |  | 115,749 |  |  |  | 22,897 |  |  |  | 138,646 |
Segment EBITDA | $ | 370,962 |  |  | $ | 169,412 |  |  | $ | 540,374 |
(1) Other direct costs primarily includes direct labor costs, delivery costs, insurance, and depreciation and amortization expense that relates to revenue-generating assets. (2) Segment selling, general, and administrative expenses includes indirect labor costs, depreciation and amortization, insurance, rent, lease, supplies, professional services, maintenance, repairs, utilities, and communications expense. (3) Total segment depreciation and amortization expense is presented in other direct costs, costs of services, and segment general and administrative expenses, based on the associated asset.
|  | For the Years Ended December 31, |
|  | 2025 |  |  | 2024 |  |  | 2023 |
Reconciliation of income or loss: |  |  |  |  |  |  |  |  |
Total Segment EBITDA |  | $ | 776,156 |  |  | $ | 599,952 |  |  | $ | 540,374 |
Segment depreciation and amortization |  |  | 134,677 |  |  |  | 135,778 |  |  |  | 138,646 |
Expenses not allocated at segment level: |  |  |  |  |  |  |  |  |
Selling, general, and administrative expenses |  |  | 317,956 |  |  |  | 329,854 |  |  |  | 321,692 |
Depreciation and amortization |  |  | 28,271 |  |  |  | 26,366 |  |  |  | 21,911 |
Loss on extinguishment of debt |  |  | — |  |  |  | 12,726 |  |  |  | — |
Interest expense, net |  |  | 157,311 |  |  |  | 190,546 |  |  |  | 271,899 |
Income tax expense (benefit) |  |  | 33,145 |  |  |  | (26,387 | ) |  |  | (31,508 | )
Net income (loss) from continuing operations |  | $ | 104,796 |  |  | $ | (68,931 | ) |  | $ | (182,266 | )

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration